Reporting owner

Frankenfield Christopher James

Reporting owner CIK 0001988344 · Chief Financial Officer

View SEC filings ↗

These transactions appear in filings associated with this reporting owner. Jointly reported quantities and amounts are unallocated; they are not this owner's individual purchases or total holdings. Names and roles reflect the relevant filing, and a reporting owner may be a person or an organization.

Reset

Transaction timeline

Who reported an acquisition, and when the transaction occurred.

PurchaseStock awardGift receivedExercise / conversionConversionOther acquisition

8 dated transactions · 1 of 1 reporting owners shown. Select one owner to focus the chart.

View timeline as a table
Transaction dateCompany / securityReporting ownersAcquisition type
Nov 21, 2025Xilio Therapeutics, Inc.Stock Option (right to buy)Frankenfield Christopher JamesStock award
Nov 21, 2025Xilio Therapeutics, Inc.Stock Option (right to buy)Frankenfield Christopher JamesStock award
Nov 21, 2025Xilio Therapeutics, Inc.Stock Option (right to buy)Frankenfield Christopher JamesStock award
Nov 21, 2025Xilio Therapeutics, Inc.Stock Option (right to buy)Frankenfield Christopher JamesStock award
Nov 21, 2025Xilio Therapeutics, Inc.Stock Option (right to buy)Frankenfield Christopher JamesStock award
Nov 21, 2025Xilio Therapeutics, Inc.Stock Option (right to buy)Frankenfield Christopher JamesStock award
Nov 21, 2025Xilio Therapeutics, Inc.Stock Option (right to buy)Frankenfield Christopher JamesStock award
Nov 21, 2025Xilio Therapeutics, Inc.Stock Option (right to buy)Frankenfield Christopher JamesStock award

Only transactions on this page are shown. Date windows end on the latest transaction date in this sample. Joint filings may appear on more than one row. Sales are not included. Share-price charts use a separate data source.

Transactions in associated filings

Reported insider acquisitions, ordered by filing date, newest first. Currency is shown only when reported.
Filed / transactedCompanyReporting ownersType / securityQuantityPrice / reference valueDetails
Trade: Xilio Therapeutics, Inc.XLO · company listings
Frankenfield Christopher JamesChief Financial Officer
Stock awardStock Option (right to buy)Derivative security · Code A300,000Not reported *Value: Not reportedCurrency not specifiedView ↗
Trade: Xilio Therapeutics, Inc.XLO · company listings
Frankenfield Christopher JamesChief Financial Officer
Stock awardStock Option (right to buy)Derivative security · Code A150,000Not reported *Value: Not reportedCurrency not specifiedView ↗
Trade: Xilio Therapeutics, Inc.XLO · company listings
Frankenfield Christopher JamesChief Financial Officer
Stock awardStock Option (right to buy)Derivative security · Code A117,000Not reported *Value: Not reportedCurrency not specifiedView ↗
Trade: Xilio Therapeutics, Inc.XLO · company listings
Frankenfield Christopher JamesChief Financial Officer
Stock awardStock Option (right to buy)Derivative security · Code A20,000Not reported *Value: Not reportedCurrency not specifiedView ↗
Trade: Xilio Therapeutics, Inc.XLO · company listings
Frankenfield Christopher JamesChief Financial Officer
Stock awardStock Option (right to buy)Derivative security · Code A45,000Not reported *Value: Not reportedCurrency not specifiedView ↗
Trade: Xilio Therapeutics, Inc.XLO · company listings
Frankenfield Christopher JamesChief Financial Officer
Stock awardStock Option (right to buy)Derivative security · Code A37,296Not reported *Value: Not reportedCurrency not specifiedView ↗
Trade: Xilio Therapeutics, Inc.XLO · company listings
Frankenfield Christopher JamesChief Financial Officer
Stock awardStock Option (right to buy)Derivative security · Code A23,786Not reported *Value: Not reportedCurrency not specifiedView ↗
Trade: Xilio Therapeutics, Inc.XLO · company listings
Frankenfield Christopher JamesChief Financial Officer
Stock awardStock Option (right to buy)Derivative security · Code A925,0000Value: 0Currency not specifiedView ↗